Amneal Pharmaceuticals (NASDAQ:AMRX) Posts Quarterly Earnings Results

Amneal Pharmaceuticals (NASDAQ:AMRX) posted its earnings results on Friday. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.03), RTT News reports. The company had revenue of $730.52 million for the quarter, compared to analysts’ expectations of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter in the prior year, the company earned $0.14 EPS. Amneal Pharmaceuticals updated its FY 2025 guidance to 0.650-0.700 EPS.

Amneal Pharmaceuticals Stock Performance

AMRX traded up $0.29 during trading on Friday, reaching $8.67. The stock had a trading volume of 2,898,126 shares, compared to its average volume of 1,319,121. The stock has a market cap of $2.69 billion, a PE ratio of -12.75 and a beta of 1.10. Amneal Pharmaceuticals has a one year low of $5.01 and a one year high of $9.48. The business has a 50-day moving average of $8.10 and a 200-day moving average of $8.32.

Insider Activity at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total value of $651,200.00. Following the transaction, the director now owns 1,888,886 shares of the company’s stock, valued at $15,375,532.04. This represents a 4.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 160,000 shares of company stock valued at $1,292,000 over the last 90 days. 26.56% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AMRX. Piper Sandler increased their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Finally, StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $10.60.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.